Men with cirrhosis have a significantly higher risk for liver-related complications ― particularly hepatocellular carcinoma ― ...

Additionally, data presented at the 2023 European Society for Medical Oncology (ESMO) Congress revealed that the combination of cadonilimab and lenvatinib as first-line treatment for advanced HCC ...

Global incidence of hepatocellular carcinoma (HCC) is rising along with its mortality burden, and more than half of the patients require systemic therapy for advanced disease. There is an ongoing ...

Accordingly, the research team conducted a study on 374 hepatocellular carcinoma patients who received Ate/Bev treatment, and the subjects consisted of 169 CPS 5 patients, 105 CPS 6 patients, and ...

For more information on this research see: Disparities In Hepatocellular Carcinoma Survival By Medicaid-status: a National Population-based Risk Analysis. European Journal of Surgical Oncology ...

Key Takeaways The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed ...

The Food and Drug Administration (FDA) has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC). Amezalpat is an ...

Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma? The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy. BMC Research Notes, 2024; 17 (1) DOI: 10.1186/s13104-024-07016-y ...

The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press release from the manufacturer.Y-90 resin microspheres (SIR-Spheres, Sirtex ...